ABSTRACT
plasma homocysteine levels in patients with renal failure, determines renal allograft dysfunction. Endothelial dysfunction probably has a role in this process. The aim of the present work was to study the influence of the C677T MTHFR gene polymorphism on plasma levels of homocysteine and folate in renal graft recipients, and their impact on chronic graft dysfunction, as well as studying the relation between chronic allograft injury and endothelial dysfunction by estimating von Willebrand factor (vWF) and measuring endothelial dependent dilatation of the brachial artery (EDD). The subjects included in this study were 32 renal allograft recipients (Group I) and 30 normal subjects as a control group (Group II
)
INTRODUCTION
The leading cause of premature mortality in renal allograft recipients is cardiovascular mortality
(1) . Also, the most important cause of chronic allograft rejection in kidney transplant has been progressive loss of function and sclerotic vascular lesions in the transplant biopsy (2) . Interestingly, fibromuscular thickening of small arterial vessels that resemble those found in chronic allograft injury was characteristic in patients suffering from homocysteinuria or other conditions with elevated plasma homocysteine (Hcy) (3,4) . In patients with chronic kidney disease, patients on maintenance hemodialysis, and in renal transplant recipients elevated homocysteine levels are commonly found (5,6,7) . Hyperhomocysteinemia is considered an independent risk factor for the development of atherosclerotic lesions in patients with impaired renal function. Thus, the elevated plasma Hcy could promote vascular sclerosis in the kidney allograft which could influence long-term renal graft survival (11) who found lower homocysteine content in blood of the renal vein of rats compared with blood obtained from the renal artery, whereas urinary excretion was negligible. Beside the homocysteine-converting enzymes cystathionine B-synthase, betainehomocysteine methyltransferase and methionine synthetase, activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) has also been detected in human kidneys. MTHFR provides 5 methyltetrahydrofolate, the active form of folate, which is necessary as a methyl donor for remethylation of homocysteine to methionine.
Recently, a polymorphism C677T in the gene coding for the enzyme MTHFR was identified. This variant, consisting of a cytosine (C) to thymine (T) at nucleotide position 677 leading to exchange of highly conserved alanine to valine in the mature protein, has been associated with reduced activity and increased thermolability of the enzyme (12) . This polymorphism may result in low active folate on the basis of decreased enzyme activity and can cause an increase of total homocysteine plasma levels. Furthermore, homozygosity for the mutant allele (TT) can confer an increased risk for vascular disease (13, 14) . The aim of the present work was to study the influence of the C677T MTHFR gene polymorphism on total homocysteine and folate plasma levels in renal graft recipients, and its impact on chronic graft dysfunction and the associated endothelial dysfunction found in those patients.
SUBJECTS & METHODS
The subjects included in this study were thirty two renal allograft recipients (Group I) 
Assay Principle:
Axis R Homocysteine EIA is designed for quantitative determination of total homocysteine in plasma or serum and is based on an enzyme -linked immunosorbent assay (ELISA). Homocysteine, mixeddisulphide and protein bound forms in the sample was reduced by the use of dithiothreitol to free homocysteine which is then enzymatically converted to s-adenosyl l-homocysteine in a separate procedure prior to the immunoassay. The concentration of homocysteine was calculated as (µmol/L)  Quantitative determination of plasma folic acid was done by a radioimmunoassay (RIA). Plasma folic acid concentration was estimated using the stimuli TRAC-SNB by radioassay Kit which was supplied by ICN pharmaceuticals Inc. Costa Mesa USA. Plasma folic acid concentration was determined as ng/ml (16) .  Quantitative determination of plasma von Willebrand factor (vWF) was done by an enzyme linked immunosorbent assay (ELISA). The values of vWF were expressed as (%) of normal (17) .  Measurement of endothelialdependent and independent vascular responses of the brachi al artery will be done by high resolution ultrasound imaging with the use of 7.5 MHz phased-array transducer attached to Hewlett Packard 1500 system (18) . During the test, vessel images were taken at rest, then during reactive hyperemia (flow mediated dilation, FMD) which is endothelial dependent dilatation (EDD), and finally after sublingual administration of isosorbide dinitrate (nitroglycerin mediated dilation, NMD) which is endothelial independent dilation (EID).
Subjects were studied in the supine position resting for 10 minutes before the test. A single investigator performed all imaging and analysis. A B-mode scan was obtained of the brachial artery in longitudinal section 5-12 cm proximal to antecubital crease, ensuring optimal visualization of anterior and posterior wall-lumen interfaces and a constant artery diameter. The diameter was calculated as the average of measurements made during 4 cardiac cycles at end diastole. All measurements were recorded on super-VHS video-tape for subsequent off-line analysis.
FMD tests were performed by selecting, at rest, three images of the brachial artery at end diastole (Bo, B1, B2 respectively). Four images were recorded during reactive hyperaemia, produced by inflation of pneumatic tourniquet to a pressure of 200 mmHg for 4.5 min. Measurements we made 30, 90, 150, 210 seconds after cuff deflation (T30, T90, T150, T210 respectively).
FMD was calculated by maximum diameter between T30, T90, T150, T210 -mean (Bo, B1, B2) *100/ mean (Bo, B1, B2).
NMD test was performed after at least a 10 min rest. The brachial artery was identified under basal conditions in the same arm position as the FMD test (three images, B3, B4, B5). Sublingual isosorbide dinitrate was then administered and three vessel images were taken 4-6 min later (N1, N2, N3). NMD was calculated by maximum diameter between N1, N2, N3, -mean (B3, B4, B5) *100/ mean (B3, B4, B5 
RESULTS
The causes of renal failure among the transplant patients varied between chronic glomerulonephritis in 12 patients (37.5%), chronic tubulointerstitial nephritis in 6 patients (18.75%), obstructive uropathy in 5 patients (15.6%), benign nephrosclerosis in 4 patients (12.5%), or unknown etiology in 5 patients (15.6%).
The renal allograft recipients were sable, with no acute rejection attacks in the last 6 month. They were on triple conventional immunosuppression protocol of cyclosporine, azathioprine, and corticosteroids.
The main socio-demographic and clinical characteristics, laboratory parameters, and brachial artery vascular response parameters among the two studied groups were shown in table I, II and III respectively. We found, among the transplant group, statistically significant correlations between plasma homocysteine and the following parameters: duration of transplantation (r = 0.789, p= 0.00), blood urea (r = 0.530, p= 0.002), serum creatinine (r = 0.398, p= 0.024), creatinine clearance (r = -0.550, p= 0.001), plasma folic acid (r = -0.870, p= 0.00), vWF (r = 0.996, p= 0.00), EDD (r = -0.980, p= 0.00). Homocysteine was not related to systolic, diastolic blood pressure, mean blood pressure, serum triglycerides, serum cholesterol and NMD. On classifying the transplant group according to their MTHFR genotypes: Group I (a): including 6 allograft recipients with homozygous-TT type. Group I (b): including 8 allograft recipients with heterozygous-CT type. Group I (c): including 18 allograft recipients with wild-CC type. The different clinical, laboratory and vascular parameters were shown in table IV. On the other hand, there was a significant positive correlation between plasma homocysteine and vWF activity and significant negative correlation between plasma homocysteine and the endothelial dependent dilatation of the brachial artery in our transplant patients. These results may point to the endothelial dysfunction found in the transplant patients, and this endothelial dysfunction which is one of the early vascular changes in atherosclerosis may be the result of the high homocysteine encountered in those patients.
The association between hyperhomocysteinemia and renal function was evidence by the significant negative correlation between plasma homocysteine and creatinine clearance in our renal allograft recipients. This association demonstrates the possible role of the hyperhomocysteinemia as a factor for chronic graft dysfunction Factors associated with hyperhomocysteinemia are age, smoking, systemic arterial hypertension, folate and vitamin B12 levels, elevated cholesterol, sedentary lifestyle and, especially, renal function (26) . The present study has shown that there was a strong significant negative correlation between folic acid and Hcy levels and hence, the possible role of superdoses of folate in treatment of this hyperhomocysteinemia (27) .
A polymorphism C677T in the gene coding for the enzyme MTHFR was identified among transplant patients. Homozygous variant was found in 6 out of 32 patients, the heterozygous variant in 8 out of 32, and the rest of patients were 18 in number of the wild type. As MTHFR plays a key role in Hcy metabolism, the effect of different MTHFR genotypes on Hcy levels were studied in this work among our renal allograft recipients. The homozygous subgroup of patients exhibit significantly higher Hcy levels and lower folic acid in comparison to the other 2 subgroups. Several studies have identified the effects of different MTHFR genotypes on Hcy metabolism in renal transplant recipients (28-30) . In addition, the endothelial derangement was more pronounced in the homozygous group in comparison with the other groups of renal allograft recipients in the present study. This endothelial dysfunction could be the link through which the hyperhomocysteinemia may exert its deleterious effects on the vascular tree. It has been shown that high levels of homocysteine induce sustained injury of arterial endothelial cells and accelerate the development of thrombosis and atherosclerosis. The mechanism by which homocysteine might cause vascular damage is unclear.
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